223 related articles for article (PubMed ID: 31720712)
1. PTH and bone material strength in hypoparathyroidism as measured by impact microindentation.
Starr JR; Tabacco G; Majeed R; Omeragic B; Bandeira L; Rubin MR
Osteoporos Int; 2020 Feb; 31(2):327-333. PubMed ID: 31720712
[TBL] [Abstract][Full Text] [Related]
2. Bone imaging in hypoparathyroidism.
Silva BC; Rubin MR; Cusano NE; Bilezikian JP
Osteoporos Int; 2017 Feb; 28(2):463-471. PubMed ID: 27577725
[TBL] [Abstract][Full Text] [Related]
3. The Clinical and Skeletal Effects of Long-Term Therapy of Hypoparathyroidism With rhPTH(1-84).
Agarwal S; McMahon DJ; Chen J; Brossfield AV; Fernando J; Bilezikian JP; Cusano NE; Rubin MR
J Bone Miner Res; 2023 Apr; 38(4):480-492. PubMed ID: 36726204
[TBL] [Abstract][Full Text] [Related]
4. Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism.
Rubin MR; Zwahlen A; Dempster DW; Zhou H; Cusano NE; Zhang C; Müller R; Bilezikian JP
J Bone Miner Res; 2016 May; 31(5):1082-8. PubMed ID: 26724790
[TBL] [Abstract][Full Text] [Related]
5. Effect of Endogenous Parathyroid Hormone on Bone Geometry and Skeletal Microarchitecture.
Hong AR; Lee JH; Kim JH; Kim SW; Shin CS
Calcif Tissue Int; 2019 Apr; 104(4):382-389. PubMed ID: 30659307
[TBL] [Abstract][Full Text] [Related]
6. Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.
Silva BC; Bilezikian JP
Rev Endocr Metab Disord; 2021 Dec; 22(4):789-802. PubMed ID: 33200346
[TBL] [Abstract][Full Text] [Related]
7. Bone Status Among Patients With Nonsurgical Hypoparathyroidism, Autosomal Dominant Hypocalcaemia, and Pseudohypoparathyroidism: A Cohort Study.
Underbjerg L; Malmstroem S; Sikjaer T; Rejnmark L
J Bone Miner Res; 2018 Mar; 33(3):467-477. PubMed ID: 29087612
[TBL] [Abstract][Full Text] [Related]
8. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
9. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).
Chen KS; Gosmanova EO; Curhan GC; Ketteler M; Rubin M; Swallow E; Zhao J; Wang J; Sherry N; Krasner A; Bilezikian JP
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3557-65. PubMed ID: 32738041
[TBL] [Abstract][Full Text] [Related]
10. Bone Material Strength Index as Measured by Impact Microindentation is Low in Patients with Primary Hyperparathyroidism.
Schoeb M; Winter EM; Sleddering MA; Lips MA; Schepers A; Snel M; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2527-e2534. PubMed ID: 33780545
[TBL] [Abstract][Full Text] [Related]
11. Bone microstructure of adult patients with non-surgical hypoparathyroidism assessed by high-resolution peripheral quantitative computed tomography.
Liu J; Chen S; Quan T; Wang Y; Wang O; Nie M; Jiang Y; Li M; Xing X; Xia W
Osteoporos Int; 2020 Nov; 31(11):2219-2230. PubMed ID: 32623488
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.
Cipriani C; Pepe J; Silva BC; Rubin MR; Cusano NE; McMahon DJ; Nieddu L; Angelozzi M; Biamonte F; Diacinti D; Hans D; Minisola S; Bilezikian JP
J Bone Miner Res; 2018 Dec; 33(12):2132-2139. PubMed ID: 30088838
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
14. Mini-review: new therapeutic options in hypoparathyroidism.
Cusano NE; Rubin MR; Sliney J; Bilezikian JP
Endocrine; 2012 Jun; 41(3):410-4. PubMed ID: 22311174
[TBL] [Abstract][Full Text] [Related]
15. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
Rubin MR; Cusano NE; Fan WW; Delgado Y; Zhang C; Costa AG; Cremers S; Dworakowski E; Bilezikian JP
J Clin Endocrinol Metab; 2016 Jul; 101(7):2742-50. PubMed ID: 27144931
[TBL] [Abstract][Full Text] [Related]
16. Skeletal Manifestations of Hypoparathyroidism.
Rubin MR
Endocrinol Metab Clin North Am; 2018 Dec; 47(4):825-837. PubMed ID: 30390816
[TBL] [Abstract][Full Text] [Related]
17. Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures.
Schoeb M; Winter EM; Malgo F; Schipper IB; van der Wal RJP; Papapoulos SE; Appelman-Dijkstra NM
Osteoporos Int; 2022 Jul; 33(7):1511-1519. PubMed ID: 35307747
[TBL] [Abstract][Full Text] [Related]
18. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism.
Rubin MR; Dempster DW; Sliney J; Zhou H; Nickolas TL; Stein EM; Dworakowski E; Dellabadia M; Ives R; McMahon DJ; Zhang C; Silverberg SJ; Shane E; Cremers S; Bilezikian JP
J Bone Miner Res; 2011 Nov; 26(11):2727-36. PubMed ID: 21735476
[TBL] [Abstract][Full Text] [Related]
19. Trabecular bone score and bone mineral density in patients with postsurgical hypoparathyroidism after total thyroidectomy for differentiated thyroid carcinoma.
Iglesias SG; Dominguez MLM; Herrero EF; Martinez-Pueyo JI; Arroba CM; Diaz-Guerra GM; Hawkins Carranza F
Surgery; 2019 Apr; 165(4):814-819. PubMed ID: 30554726
[TBL] [Abstract][Full Text] [Related]
20. PTH treatment in hypoparathyroidism.
Sikjaer T; Rejnmark L; Mosekilde L
Curr Drug Saf; 2011 Apr; 6(2):89-99. PubMed ID: 21524246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
